On November 24, 2021, G9pharma co., LTD closed the transaction and raised KRW 9,999,999,775 for shares in the transaction. The bonds will now mature on December 2, 2024 and will be convertible into 1,084,010 shares at a conversion price of KRW 7,380 per share. The conversion period will start from December 2, 2022 and ends on November 29, 2024. The transaction is expected to close on December 2, 2021. On November 30, 2021, the company amended the terms of the transaction and will now issue KRW 4,040,000,000 convertible bonds. The transaction will include participation from returning investor, Meritz Securities Co., Ltd., Investment Arm. The bonds will now mature on December 2, 2024 and will be convertible into 547,425 shares at a conversion price of KRW 7,380 per share. The conversion period will start from December 2, 2022 and ends on November 29, 2024. The transaction is expected to close on December 2, 2021. On December 2, 2021, the company announced that it has cancelled the transaction for series 16 convertible bonds.